These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 21609685)

  • 1. Automated luminescence-based cytochrome P450 profiling using a simple, elegant robotic platform.
    Larson B; Banks P; Cali JJ; Sobol M; Shultz S
    J Lab Autom; 2011 Feb; 16(1):47-55. PubMed ID: 21609685
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Luminogenic cytochrome P450 assays.
    Cali JJ; Ma D; Sobol M; Simpson DJ; Frackman S; Good TD; Daily WJ; Liu D
    Expert Opin Drug Metab Toxicol; 2006 Aug; 2(4):629-45. PubMed ID: 16859410
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of a miniaturized 384-well high throughput screen for the detection of substrates of cytochrome P450 2D6 and 3A4 metabolism.
    Kariv I; Fereshteh MP; Oldenburg KR
    J Biomol Screen; 2001 Apr; 6(2):91-9. PubMed ID: 11689103
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-throughput mass spectrometric cytochrome P450 inhibition screening.
    Lim KB; Ozbal CC; Kassel DB
    Methods Mol Biol; 2013; 987():25-50. PubMed ID: 23475665
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Insights into molecular basis of cytochrome p450 inhibitory promiscuity of compounds.
    Cheng F; Yu Y; Zhou Y; Shen Z; Xiao W; Liu G; Li W; Lee PW; Tang Y
    J Chem Inf Model; 2011 Oct; 51(10):2482-95. PubMed ID: 21875141
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The interaction potential of herbal medicinal products: a luminescence-based screening platform assessing effects on cytochrome P450 and its use with devil's claw (Harpagophyti radix) preparations.
    Modarai M; Suter A; Kortenkamp A; Heinrich M
    J Pharm Pharmacol; 2011 Mar; 63(3):429-38. PubMed ID: 21749392
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of human drug metabolizing cytochrome P450 enzymes by plant isoquinoline alkaloids.
    Salminen KA; Meyer A; Jerabkova L; Korhonen LE; Rahnasto M; Juvonen RO; Imming P; Raunio H
    Phytomedicine; 2011 Apr; 18(6):533-8. PubMed ID: 20851588
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development and validation of a liquid-chromatography high-resolution tandem mass spectrometry approach for quantification of nine cytochrome P450 (CYP) model substrate metabolites in an in vitro CYP inhibition cocktail.
    Dinger J; Meyer MR; Maurer HH
    Anal Bioanal Chem; 2014 Jul; 406(18):4453-64. PubMed ID: 24830396
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Automated high throughput ADME assays for metabolic stability and cytochrome P450 inhibition profiling of combinatorial libraries.
    Jenkins KM; Angeles R; Quintos MT; Xu R; Kassel DB; Rourick RA
    J Pharm Biomed Anal; 2004 Mar; 34(5):989-1004. PubMed ID: 15019033
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Highly miniaturized formats for in vitro drug metabolism assays using vivid fluorescent substrates and recombinant human cytochrome P450 enzymes.
    Trubetskoy OV; Gibson JR; Marks BD
    J Biomol Screen; 2005 Feb; 10(1):56-66. PubMed ID: 15695344
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro drug interactions of cytochrome p450: an evaluation of fluorogenic to conventional substrates.
    Cohen LH; Remley MJ; Raunig D; Vaz AD
    Drug Metab Dispos; 2003 Aug; 31(8):1005-15. PubMed ID: 12867489
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-Throughput Cytochrome P450 Cocktail Inhibition Assay for Assessing Drug-Drug and Drug-Botanical Interactions.
    Li G; Huang K; Nikolic D; van Breemen RB
    Drug Metab Dispos; 2015 Nov; 43(11):1670-8. PubMed ID: 26285764
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolism profiling, and cytochrome P450 inhibition & induction in drug discovery.
    Yan Z; Caldwell GW
    Curr Top Med Chem; 2001 Nov; 1(5):403-25. PubMed ID: 11899105
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Simultaneous determination of the inhibitory potency of herbal extracts on the activity of six major cytochrome P450 enzymes using liquid chromatography/mass spectrometry and automated online extraction.
    Unger M; Frank A
    Rapid Commun Mass Spectrom; 2004; 18(19):2273-81. PubMed ID: 15384148
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-throughput cytochrome P450 (CYP) inhibition screening via a cassette probe-dosing strategy. VI. Simultaneous evaluation of inhibition potential of drugs on human hepatic isozymes CYP2A6, 3A4, 2C9, 2D6 and 2E1.
    Bu HZ; Magis L; Knuth K; Teitelbaum P
    Rapid Commun Mass Spectrom; 2001; 15(10):741-8. PubMed ID: 11344532
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of the inhibitory potential of Ginkgo biloba, Echinacea purpurea, and Serenoa repens on the metabolic activity of cytochrome P450 3A4, 2D6, and 2C9.
    Yale SH; Glurich I
    J Altern Complement Med; 2005 Jun; 11(3):433-9. PubMed ID: 15992226
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of a fluorescence-based, ultra high-throughput screening platform for nanoliter-scale cytochrome p450 microarrays.
    Sukumaran SM; Potsaid B; Lee MY; Clark DS; Dordick JS
    J Biomol Screen; 2009 Jul; 14(6):668-78. PubMed ID: 19525490
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Automated assessment of time-dependent inhibition of human cytochrome P450 enzymes using liquid chromatography-tandem mass spectrometry analysis.
    Atkinson A; Kenny JR; Grime K
    Drug Metab Dispos; 2005 Nov; 33(11):1637-47. PubMed ID: 16049126
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
    Sakatis MZ; Reese MJ; Harrell AW; Taylor MA; Baines IA; Chen L; Bloomer JC; Yang EY; Ellens HM; Ambroso JL; Lovatt CA; Ayrton AD; Clarke SE
    Chem Res Toxicol; 2012 Oct; 25(10):2067-82. PubMed ID: 22931300
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Automated triplexed hepatocyte-based viability and CYP1A and -3A induction assays.
    Larson B; Moeller T; Banks P; Cali JJ
    J Biomol Screen; 2011 Sep; 16(8):895-902. PubMed ID: 21693767
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.